Introduction
============

Neuroblastoma has been recognized as one of the most commonly diagnosed extracranial solid tumor in infancy, which constitute about 7-10% of all childhood cancers. It is the third leading cause of cancer-related death in children [@B1]. The peak incidence of neuroblastoma is in children, and the median age at diagnosis is around 17 months [@B2]. It may arise anywhere of the sympathetic nervous system, and mainly arise within the abdomen and adrenal medulla [@B3]. The incidence rate of neuroblastoma is about 1 in 7000 live newborns worldwide, and nearly 700 new cases occur per year in the United States [@B4]. It is also one of the most common solid tumors in the Chinese infants, with an incidence rate of approximately 7.7 per million [@B5]. The majority of neuroblastomas are sporadically, and only about 1% of neuroblastoma patients have a family history [@B6]. So far, the etiology of neuroblastoma is not well understood [@B7]. Case-control studies and family studies play important roles in discovering genetic component of the neuroblastoma susceptibility [@B8]. For example, Han et al. [@B9] performed a case-control study among Chinese with 203 neuroblastoma patients and 411 controls. They found significant association of *FAS* -1377 G/A and *FASL* -844 T/C polymorphisms with neuroblastoma susceptibility.

Genome-wide association studies (GWASs) have proven to be a powerful and hypothesis-free method to discover genes that confer susceptibility to complex diseases including cancers [@B10]. To date, five GWASs on the neuroblastoma have been performed, mainly in European descents, and several neuroblastoma susceptibility related loci have been identified [@B11]-[@B15]. The first GWAS performed by Maris et al. included 1032 neuroblastoma cases and 2043 controls at the discovery stage, and 720 neuroblastoma cases and 2128 controls in the validation stage [@B11]. They found that three single nucleotide polymorphisms (SNPs) located on chromosome 6p22 were significantly associated with neuroblastoma susceptibility. When the analysis was restricted to only 397 high-risk neuroblastoma cases and 2043 controls [@B11], they observed new significant association between neuroblastoma susceptibility and six SNPs at 2q35 within the *BRCA1 associated RING domain 1* (*BARD1*) locus. Of them, the rs6435862 T\>G and rs3768716 A\>G are the two most significant SNPs. The association between GWAS-identified polymorphisms in the *BARD1* gene and neuroblastoma susceptibility has been validated in the African-Americans [@B16] as well as Italians [@B17], but not in Asians. With this in mind, we carried out the current hospital-based case-control study with a total of 201 neuroblastoma patients and 531 cancer-free controls to explore the association between three GWAS-identified*BARD1* gene polymorphisms (rs7585356 G\>A, rs6435862 T\>G and rs3768716 A\>G) and neuroblastoma susceptibility in a Southern Chinese population.

Materials and methods
=====================

Study subjects
--------------

We enrolled a total of 201 neuroblastoma cases as well as 531 cancer-free controls in this hospital-based case-control study as we described previously [@B18]. All the neuroblastoma cases were newly diagnosed and histopathologically confirmed individuals and recruited from the Guangzhou Women and Children\'s Medical Center. The cancer-free controls were randomly selected from children receiving a routine physical examination in the same hospital and matched to cases on age and gender (frequency matching). Both of the cases and controls were ethnic Chinese Han subjects. Exclusion criteria were as follows: other types of cancer, secondary/recurrent malignancies, and receipt of chemotherapy or radiotherapy before recruitment. At recruitment, information on each subject (e.g., age, gender and personal medical histories) was collected by structured questionnaire or medical records. This study was approved by the Institutional Review Board of Guangzhou Women and Children\'s Medical Center. Written informed consent was obtained from all participants or the children\'s guardians.

Polymorphism analysis
---------------------

Genomic DNA was mainly extracted from 2 mL blood sample using the TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China) according to the manufacturer\'s instructions. DNA samples were prepared as we described previously [@B19], [@B20]. Briefly, all the DNA samples were diluted to a concentration of 10 ng/μL and loaded in the 96-well plates. Genotyping for the three GWAS-identified *BARD1* SNPs (rs7585356 G\>A, rs6435862 T\>G, and rs3768716 A\>G) [@B12] was performed in the 384-well plate using Taqman method as published previously [@B19]. As shown in **[Supplemental Table 1](#SM1){ref-type="supplementary-material"}**, these three SNPs can also capture an additional of 10 polymorphisms as predicted by SNPinfo software (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>). Moreover, 10% of samples were selected randomly for repeat assay, and the results were 100% concordant.

Statistical analysis
--------------------

Distributions of demographic variables and genotypes between cases and controls were compared by χ^2^ test. Goodness-of-fit χ^2^test was performed to detect deviation from Hardy-Weinberg equilibrium in controls. Odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for age and gender were used to assess the strength of associations between selected polymorphisms and neuroblastoma susceptibility by using unconditional multivariate logistic regression analysis. All statistical analyses were performed using SAS software (version 9.1; SAS Institute, Cary, NC), with a significance level of 0.05. All tests were two-sided.

Results
=======

Population characteristics
--------------------------

The distributions of the demographic characteristics of the neuroblastoma cases and controls were summarized in **[Supplemental Table 2](#SM1){ref-type="supplementary-material"}**. The current study included 201 neuroblastoma patients and 531 age- and gender-matched cancer-free controls. No statistical significant differences were observed in the distributions of age (*P*=0.788) and gender (*P*=0.452) between cases and controls. According to INSS criteria [@B21], 50 (24.88%), 54 (26.87%), 34 (16.92%), 49 (24.38%) and 7 (3.48%) patients had clinical stage I, II, III, IV and 4s neuroblastoma, respectively. In term of tumor site, the neuroblastomas mainly occurred in adrenal glands (N=30, 14.93%), retroperitoneal regions (N=50, 24.86%), and mediastinum (N=80, 39.80%).

Association between BARD1 SNPs and neuroblastoma susceptibility
---------------------------------------------------------------

The genotype frequencies of the three selected SNPs and their associations with neuroblastoma susceptibility were shown in **Table [1](#T1){ref-type="table"}**. We observed that frequency distributions of all of the *BARD1*polymorphisms were consistent with the Hardy-Weinberg equilibrium (*P*=0.948 for rs7585356 G\>A, *P*=0.205 for rs6435862 T\>G, and *P*=0.415 for rs3768716 A\>G polymorphism) in control subjects. We failed to observe any significant association between the rs7585356 G\>A polymorphism and neuroblastoma susceptibility (AG vs. GG: adjusted OR=0.91, 95% CI=0.64-1.27; AA vs. GG: adjusted OR=0.61, 95% CI=0.33-1.13; AG/AA vs. GG: adjusted OR=0.85, 95% CI=0.61-1.17 and GG/AG vs. AA: adjusted OR=0.64, 95% CI=0.35-1.16). As to the rs6435862 T\>G polymorphism, we found a borderline significant increase in the neuroblastoma risk only for the rs6435862 TG carriers (adjusted OR=1.40, 95% CI=0.98-2.00, *P*=0.067) when compared to the TT carriers. A similar trend toward increased risk were observed for the rs3768716 heterozygotes (AG vs. AA: adjusted OR=1.40, 95% CI=0.98-2.00, *P*=0.076). We did not find any significant association for the risk genotypes.

Stratified analysis of BARD1 polymorphisms and neuroblastoma susceptibility
---------------------------------------------------------------------------

We performed stratified analyses by age, gender, sites of origin, and clinical stages to evaluate the effects of variant genotypes on the risk of neuroblastoma (**Table [2](#T2){ref-type="table"}**). Among the girls, carrier of rs7585356 AG or AA genotype had an odds ratio of 0.55 (adjusted OR=0.55, 95% CI=0.33-0.92) for developing neuroblastoma, compared with carriers of GG genotype, suggesting a protective effect of rs7585356 on girls. Moreover, a comparison of homozygotes and heterozygotes versus wild-types indicated that the rs6435862 T\>G polymorphism increased the risk of neuroblastoma among the kids older than 12 months (adjusted OR=1.55, 95% CI=1.04-2.31), with tumor in adrenal gland (adjusted OR=2.94, 95% CI=1.40-6.18), and with clinical stages III+IV disease (adjusted OR=1.75, 95% CI=1.09-2.84), when compared to the TT genotype, we observed the TG/GG carriers have an increased neuroblastoma susceptibility. Similar risk effects were observed for the rs3768716 A\>G polymorphism among children older than 12 months (adjusted OR=1.54, 95% CI=1.04-2.28), with tumor in adrenal gland (adjusted OR=2.55, 95% CI=1.21-5.37), and with clinical stages III+IV disease (adjusted OR=1.69, 95% CI=1.05-2.72).

Discussion
==========

In the current hospital-based case-control study, we explored the association of three *BARD1* gene polymorphisms with neuroblastoma susceptibility in 201 patients and 531 cancer-free controls. To the best of our knowledge, this is the first investigation to validate GWAS-identified SNPs at 2q35 within the*BARD1* gene in Southern Chinese population. We found the frequency of the TG/GG genotypes of the rs6435862 T\>G polymorphism and the AG/GG genotypes of the rs3768716 A\>G polymorphism were significantly higher than that of their respective wide-type genotypes in older subjects, and those with disease originated from adrenal gland or late clinical stage neuroblastoma. The results from the current study suggest that rs6435862 T\>G and rs3768716 A\>G polymorphisms were significantly associated with neuroblastoma susceptibility for subjects with late clinical stage neuroblastoma, which were consistent with the findings from previous GWAS studies [@B12].

The *BARD1* gene is located at chromosome 2q35, containing 13 exons. This gene encodes a protein that can interact with the N-terminal region of BRCA1 both *in vivo* and *in vitro* [@B22]. The*BARD1* gene has been recognized as a classically tumor suppressor for the following reasons: 1) it directly interacts with the BRCA1 through their respective RING domains; 2) it plays an important role in double-strand break repair and ubiquitination; 3) it serves as a mediator in the process of apoptosis by binding to and stabilizing p53 [@B23]; 4) it also plays roles in the regulation of cell growth, including the products of dominant protooncogenes and tumor suppressor genes [@B24]. Somatically acquired missense *BARD1* mutations were observed in the breast and ovarian cancer patients [@B25]. Polymorphisms of *BARD1*such as the Cys557Ser may contribute to the susceptibility of breast cancer [@B26]-[@B28]. However, a meta-analysis collecting a total of 14 studies with 11870 cases and 7687 controls did not validate the significant association between Cys557Ser mutation and breast cancer risk [@B29].

SNPs may change the encoding amino acids (non-synonymous SNPs), may be silent (synonymous SNPs), or may occur in the non-coding regions. The non-synonymous SNPs could affect the function and expression levels of genes and consequentially result in disease [@B30]. There are at least 4941 SNPs in the *BARD1* gene region (<http://www.ncbi.nlm.nih.gov/projects/SNP>). Among all the identified *BARD1*SNPs, six common polymorphisms have been found to be associated with neuroblastoma susceptibility in a previous GWAS [@B12]. In this study, Capasso et al. only focused on high-risk neuroblastoma patients which were enrolled in their first neuroblastoma GWAS [@B11], a total of 397 cases and 2043 controls were included in the discover stage, and six SNPs at 2q35 within the *BARD1* were found to be significantly associated with increased neuroblastoma susceptibility. A total of 189 cases and 1178 controls were used to further validated the significant SNPs. Of them, the rs6435862 T\>G and rs3768716 A\>G polymorphism were the most significant for high-risk neuroblastoma patients, with allelic OR of 1.68 for each polymorphism.

In the first replication study carried out among African-Americans, comprising 390 neuroblastoma patients, Latorre et al. [@B16] found that all of the included SNPs were associated with increased neuroblastoma risk with one exception that they failed to confirm the association of the first GWAS-identified SNPs within the*FLJ22536* gene with neuroblastoma susceptibility. In another replication study in Italians with 370 neuroblastoma cases and 809 controls, Capasso et al. [@B17] proved that the *BARD1* SNPs were associated with neuroblastoma susceptibility, and the association was more prominent for high-risk neuroblastoma patients. In the current study, we chose the two most significant SNPs (rs6435862 T\>G and rs3768716 A\>G) as well as the one located in the 3\' UTR region (rs7585356 G\>A). We failed to find the significant associations between the selected SNPs and neuroblastoma susceptibility for overall subjects. Interestingly, in the stratified analysis by clinical stages, we found subjects carrying the rs6435862 TG/GG or rs3768716 AG/GG genotypes have a significantly increased risk of developing neuroblastoma among the ISSN clinical stages III/IV neuroblastoma patients. The reason we failed to validate the results from the studies conducted among African-Americans and Italians may be ascribed to the ethnicity difference. For example, the minor allele frequency (MAF) of the rs6435862 T\>G was 0.18 for our neuroblastoma cases and 0.16 for the cancer-free controls, 0.34 for African-American cases and 0.26 for and controls, and 0.43 for Italian cases and 0.26 for controls. As to the rs3768716 A\>G polymorphism, the MAF for the cases and controls in the current study was 0.21 and 0.18, 0.10 and 0.07 for African-American cases and controls, and 0.35 and 0.23 for Italian cases and controls, respectively. Given the possible differences in the MAF and pattern of linkage disequilibrium among Asians, African-Americans and Caucasians, the effects of the studied genetic susceptibility to neuroblastoma may vary, which may partially explain the failure to validate the significant results from African-Americans and Italians. Besides, the first GWAS also did not detect the association of the *BARD1* polymorphisms with neuroblastoma risk in all subjects [@B11]. We speculate that these SNPs within the *BARD1* gene may have mild contribution to the development of neuroblastoma. The relatively small sample size of this study might have limited statistical power to detect such mild effect of studied SNPs.

This is the first validation study for the association between *BARD1* gene polymorphisms and neuroblastoma susceptibility in Southern Chinese children. There were several potential limitations should be addressed in the present study. First, only 201 patients were included, the relatively small sample size may have reduced the statistical power of the study. Second, we only included three polymorphisms in the *BARD1* gene, more polymorphisms especially the potentially functional SNPs not contained in GWASs remain to be replicated. Finally, this study was restricted to Chinese Han ethnicity subjects from Southern China, and the results should be extrapolated to other ethnic groups cautiously.

In conclusion, in the current study, we found a significant association of the *BARD1*gene rs6435862 T\>G and rs3768716 A\>G polymorphisms with an increased neuroblastoma susceptibility for older children, children with adrenal gland-originated or late clinical stage neuroblastoma subjects in a Chinese Han population. Further prospective studies with larger sample sizes including different ethnic populations and further functional studies are required to validate our results.
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GWAS

:   genome-wide association study

SNP

:   single nucleotide polymorphism

*BARD1*

:   *BRCA1 associated RING domain 1*

OR

:   odds ratio

CI

:   confidence interval

MAF

:   minor allele frequency.

###### 

Logistic regression analysis of associations between *BARD1* polymorphisms and neuroblastoma susceptibility.

  Genotype                            Cases (N=201)   Controls (N=531)   *P*^a^     Crude OR (95% CI)   *P*     Adjusted OR (95% CI) ^b^   *P*^b^
  ----------------------------------- --------------- ------------------ ---------- ------------------- ------- -------------------------- --------
  rs7585356 (HWE=0.948)                                                                                                                    
  GG                                  97 (48.26)      235 (44.26)                   1.00                        1.00                       
  AG                                  89 (44.28)      237 (44.63)                   0.91 (0.65-1.28)    0.585   0.91 (0.64-1.27)           0.567
  AA                                  15 (7.46)       59 (11.11)                    0.62 (0.33-1.14)    0.122   0.61 (0.33-1.13)           0.114
  Additive                                                               0.295      0.84 (0.65-1.08)    0.160   0.83 (0.65-1.07)           0.148
  Dominant                            104 (51.74)     296 (55.74)        0.332      0.85 (0.62-1.18)    0.332   0.85 (0.61-1.17)           0.315
  Recessive                           186 (92.54)     472 (88.89)        0.144      0.65 (0.36-1.17)    0.147   0.64 (0.35-1.16)           0.139
  rs6435862 (HWE=0.205)                                                                                                                    
  TT                                  132 (65.67)     381 (71.75)                   1.00                        1.00                       
  TG                                  64 (31.84)      133 (25.05)                   1.40 (0.97-1.99)    0.072   1.40 (0.98-2.00)           0.067
  GG                                  5 (2.49)        17 (3.20)                     0.85 (0.31-2.35)    0.752   0.84 (0.31-2.34)           0.745
  Additive                                                               0.172      1.20 (0.89-1.62)    0.222   1.21 (0.90-1.63)           0.216
  Dominant                            69 (34.33)      150 (28.25)        0.109      1.33 (0.94-1.88)    0.109   1.34 (0.94-1.89)           0.104
  Recessive                           196 (97.51)     514 (96.80)        0.614      0.77 (0.28-2.12)    0.615   0.77 (0.28-2.10)           0.604
  rs3768716 (HWE=0.415)                                                                                                                    
  AA                                  125 (62.19)     364 (68.55)                   1.00                        1.00                       
  AG                                  69 (34.33)      148 (27.87)                   1.36 (0.96-1.93)    0.087   1.38 (0.97-1.96)           0.076
  GG                                  7 (3.48)        19 (3.58)                     1.07 (0.44-2.61)    0.877   1.06 (0.43-2.57)           0.907
  Additive                                                               0.230      1.22 (0.92-1.63)    0.170   1.23 (0.92-1.64)           0.163
  Dominant                            76 (37.81)      167 (31.45)        0.103      1.33 (0.94-1.86)    0.103   1.34 (0.95-1.88)           0.094
  Recessive                           194 (96.52)     512 (96.42)        0.950      0.97 (0.40-2.35)    0.951   0.96 (0.40-2.31)           0.918
  Combined effect of risk genotypes                                                                                                        
  0                                   49 (24.38)      129 (24.29)        0.171^c^   1.00                        1.00                       
  1                                   77 (38.31)      244 (45.95)                   0.83 (0.55-1.26)    0.384   0.83 (0.54-1.25)           0.369
  2                                   53 (26.37)      105 (19.77)                   1.33 (0.83-2.12)    0.232   1.34 (0.84-2.13)           0.225
  3                                   22 (10.95)      53 (9.98)                     1.09 (0.60-1.98)    0.770   1.10 (0.60-1.99)           0.763
  1-3                                 152 (75.62)     402 (75.71)        0.981      1.00 (0.68-1.45)    0.981   0.99 (0.68-1.45)           0.973

^a^ *χ^2^* test for genotype distributions between neuroblastoma patients and controls.

^b^Adjusted for age and gender.

^c^ Additive models.

###### 

Stratification analysis for association between *BARD1* genotypes and neuroblastoma susceptibility.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables         rs7585356\         Adjusted OR ^a^ (95% CI)   *P*^a^             rs6435862 (cases/controls)   Adjusted OR ^a^(95% CI)   *P*^a^   rs3768716 (cases/controls)   Adjusted OR ^a^(95% CI)   *P*^a^                                       
                    (cases/controls)                                                                                                                                                                                                                     
  ----------------- ------------------ -------------------------- ------------------ ---------------------------- ------------------------- -------- ---------------------------- ------------------------- -------- -------- ------------------ ------- --
  Age, month                                                                                                                                                                                                                                             

  \<12              22/67              32/78                      1.23 (0.65-2.32)   0.529                        41/105                    13/40    0.85 (0.41-1.77)             0.670                     38/98    16/47    0.90 (0.45-1.78)   0.756   

  ≥12               75/168             72/218                     0.74 (0.50-1.08)   0.119                        91/276                    56/110   1.55 (1.04-2.31)             0.032                     87/266   60/120   1.54 (1.04-2.28)   0.032   

  Gender                                                                                                                                                                                                                                                 

  Females           48/102             34/131                     0.55 (0.33-0.92)   0.022                        53/160                    29/73    1.20 (0.70-2.04)             0.504                     49/150   33/83    1.22 (0.73-2.04)   0.458   

  Males             49/133             70/165                     1.15 (0.75-1.77)   0.522                        79/221                    40/77    1.45 (0.92-2.30)             0.113                     76/214   43/84    1.44 (0.92-2.27)   0.112   

  Sites of origin                                                                                                                                                                                                                                        

  Adrenal gland     15/235             15/296                     0.80 (0.38-1.66)   0.543                        14/381                    16/150   2.94 (1.40-6.18)             0.005                     14/364   16/167   2.55 (1.21-5.37)   0.014   

  Retroperitoneal   21/235             29/296                     1.09 (0.61-1.97)   0.767                        36/381                    14/150   1.00 (0.52-1.91)             0.996                     36/364   14/167   0.87 (0.45-1.65)   0.660   

  Mediastinum       43/235             37/296                     0.68 (0.43-1.10)   0.114                        54/381                    26/150   1.22 (0.73-2.02)             0.450                     51/364   29/167   1.23 (0.75-2.01)   0.410   

  Others            10/235             7/296                      0.56 (0.21-1.49)   0.242                        15/381                    2/150    0.35 (0.08-1.57)             0.172                     13/364   4/167    0.70 (0.22-2.18)   0.534   

  Clinical stages                                                                                                                                                                                                                                        

  I+II+4s           52/235             59/296                     0.90 (0.60-1.36)   0.621                        76/381                    35/150   1.18 (0.75-1.83)             0.477                     73/364   38/167   1.13 (0.73-1.75)   0.580   

  III+IV            41/235             42/296                     0.80 (0.50-1.27)   0.347                        49/381                    34/150   1.75 (1.09-2.84)             0.022                     47/364   36/167   1.69 (1.05-2.72)   0.031   

                                                                                                                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted for age and gender.
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